EE05537B1 - Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks - Google Patents

Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks

Info

Publication number
EE05537B1
EE05537B1 EEP200300355A EEP200300355A EE05537B1 EE 05537 B1 EE05537 B1 EE 05537B1 EE P200300355 A EEP200300355 A EE P200300355A EE P200300355 A EEP200300355 A EE P200300355A EE 05537 B1 EE05537 B1 EE 05537B1
Authority
EE
Estonia
Prior art keywords
neublastin
methods
polymeric conjugates
conjugates
polymeric
Prior art date
Application number
EEP200300355A
Other languages
English (en)
Estonian (et)
Inventor
W. Y. Sah Dinah
Blake Pepinsky R.
Ann Borjack-Sjodin Paula
S. Miller Stephan
Rossomando Anthony
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300355A publication Critical patent/EE200300355A/xx
Publication of EE05537B1 publication Critical patent/EE05537B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
EEP200300355A 2001-02-01 2002-01-25 Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks EE05537B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Publications (2)

Publication Number Publication Date
EE200300355A EE200300355A (et) 2003-10-15
EE05537B1 true EE05537B1 (et) 2012-04-16

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300355A EE05537B1 (et) 2001-02-01 2002-01-25 Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks

Country Status (36)

Country Link
EP (2) EP1355936B1 (xx)
JP (2) JP4259868B2 (xx)
KR (2) KR100960063B1 (xx)
CN (1) CN1500095B (xx)
AR (1) AR035077A1 (xx)
AT (1) ATE365748T1 (xx)
AU (1) AU2002247037B2 (xx)
BG (1) BG66393B1 (xx)
BR (1) BR0206852A (xx)
CA (1) CA2436407C (xx)
CY (1) CY1106886T1 (xx)
CZ (1) CZ20032080A3 (xx)
DE (1) DE60220879T2 (xx)
DK (1) DK1355936T3 (xx)
EA (1) EA009771B1 (xx)
EE (1) EE05537B1 (xx)
ES (1) ES2289091T3 (xx)
GE (1) GEP20063916B (xx)
HK (1) HK1057759A1 (xx)
HU (1) HU228973B1 (xx)
IL (2) IL156941A0 (xx)
IS (1) IS2867B (xx)
MX (1) MXPA03006805A (xx)
MY (1) MY143685A (xx)
NO (1) NO332150B1 (xx)
NZ (1) NZ527863A (xx)
PL (1) PL211162B1 (xx)
PT (1) PT1355936E (xx)
RS (1) RS50857B (xx)
SG (1) SG149685A1 (xx)
SI (1) SI1355936T1 (xx)
SK (1) SK288123B6 (xx)
TR (1) TR200301208T2 (xx)
UA (2) UA100967C2 (xx)
WO (1) WO2002060929A2 (xx)
ZA (1) ZA200305733B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2002060929A2 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
EP3669887A1 (en) * 2002-01-18 2020-06-24 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
CN101166753A (zh) * 2003-01-31 2008-04-23 比奥根艾迪克Ma公司 突变神经胚素的聚合物偶联物
ES2479942T3 (es) 2003-04-18 2014-07-25 Biogen Idec Ma Inc. Neublastina glucosilada conjugada con polímero
ATE423134T1 (de) * 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
AU2005277227B2 (en) * 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
RS51453B (en) 2004-08-19 2011-04-30 Biogen Idec Ma Inc. NEUBLASTIN
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
WO2008031612A1 (en) 2006-09-15 2008-03-20 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
JP5583005B2 (ja) * 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
BR112014010406A2 (pt) * 2011-11-02 2017-04-25 Genentech Inc cromatografia de sobrecarga e eluto
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
EP1137774A2 (en) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
WO2002060929A2 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same

Also Published As

Publication number Publication date
TR200301208T2 (tr) 2005-05-23
BG108111A (bg) 2004-12-30
SK9712003A3 (en) 2004-01-08
JP2005503763A (ja) 2005-02-10
CZ20032080A3 (cs) 2003-10-15
WO2002060929A3 (en) 2003-03-06
KR100960063B1 (ko) 2010-05-31
HU228973B1 (en) 2013-07-29
UA82983C2 (ru) 2008-06-10
PT1355936E (pt) 2007-09-28
ATE365748T1 (de) 2007-07-15
ZA200305733B (en) 2005-02-23
KR20030074766A (ko) 2003-09-19
SI1355936T1 (sl) 2007-12-31
IL156941A0 (en) 2004-02-08
SK288123B6 (sk) 2013-09-03
PL372101A1 (en) 2005-07-11
IS2867B (is) 2014-02-15
WO2002060929A2 (en) 2002-08-08
ES2289091T3 (es) 2008-02-01
HUP0500637A2 (hu) 2005-09-28
NZ527863A (en) 2006-09-29
JP2009039135A (ja) 2009-02-26
HUP0500637A3 (en) 2010-01-28
PL211162B1 (pl) 2012-04-30
EA200300852A1 (ru) 2004-06-24
CA2436407C (en) 2011-08-30
EP1355936B1 (en) 2007-06-27
IL156941A (en) 2008-11-03
YU61003A (sh) 2006-05-25
IS6879A (is) 2003-07-17
SG149685A1 (en) 2009-02-27
MXPA03006805A (es) 2003-11-13
MY143685A (en) 2011-06-30
EP1862475A1 (en) 2007-12-05
JP4259868B2 (ja) 2009-04-30
UA100967C2 (ru) 2013-02-25
NO20033441L (no) 2003-10-01
KR100872807B1 (ko) 2008-12-09
AR035077A1 (es) 2004-04-14
BR0206852A (pt) 2005-05-03
BG66393B1 (bg) 2013-11-29
CN1500095A (zh) 2004-05-26
EA009771B1 (ru) 2008-04-28
DE60220879D1 (de) 2007-08-09
DK1355936T3 (da) 2007-10-29
JP4423338B2 (ja) 2010-03-03
CY1106886T1 (el) 2012-09-26
EE200300355A (et) 2003-10-15
KR20080098662A (ko) 2008-11-11
NO20033441D0 (no) 2003-08-01
CA2436407A1 (en) 2002-08-08
DE60220879T2 (de) 2008-03-06
CN1500095B (zh) 2010-06-16
HK1057759A1 (en) 2004-04-16
RS50857B (sr) 2010-08-31
NO332150B1 (no) 2012-07-09
EP1355936A2 (en) 2003-10-29
AU2002247037B2 (en) 2007-08-16
GEP20063916B (en) 2006-09-11

Similar Documents

Publication Publication Date Title
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
EE200300528A (et) Cripto valku blokeerivad antikehad ja nende kasutamine
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
CY2013032I1 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
EE05537B1 (et) Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks
EE05169B1 (et) Asendatud oksasolidinoonid ja nende kasutamine
DE50112013D1 (de) Deodorantien und antiperspirantien
EE200200550A (et) Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine
AR028622A1 (es) Derivados de tropano utiles en terapia
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
EE200200626A (et) Antraniilamiidid ja nende kasutamine ravimitena
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
FI20010222A0 (fi) Lääketieteellisesti hammashoidolliset polymeerikomposiitit ja -koostumukset
DE60216254D1 (de) Acrylkautschukzusammensetzung und vulkanisat
BRPI0208558A2 (pt) preparado de combinação de estrogênio-gestagênio e uso
EE05333B1 (et) Makroliidhendite konjugaadid p?letikuvastaste henditega ja nende kasutamine
EE200300193A (et) Asendatud bensimidasoolid, nende kasutamine ja ravim
FI20011671A0 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
DE60208700D1 (de) Schälgerät und zugehörige verfahren
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
FI20001715A0 (fi) Rankoihin liittyvät järjestelyt ja menetelmät
EE200300339A (et) Helicobacter pylory uudsed retseptorid ja nende kasutamine
DE60217539D1 (de) Leichtathletikschuh

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20160125